Captrust Financial Advisors An2 Therapeutics, Inc. Transaction History
Captrust Financial Advisors
- $46.7 Billion
- Q3 2025
A detailed history of Captrust Financial Advisors transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 40,000 shares of ANTX stock, worth $45,599. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,000
Previous 40,000
-0.0%
Holding current value
$45,599
Previous $42,000
19.05%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ANTX
# of Institutions
35Shares Held
7.57MCall Options Held
0Put Options Held
0-
Almitas Capital LLC Santa Monica, CA1.43MShares$1.63 Million0.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.08MShares$1.23 Million0.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY589KShares$671,7060.67% of portfolio
-
Stonepine Capital Management, LLC Bend, OR564KShares$642,8600.58% of portfolio
-
Bank Of Nova Scotia459KShares$523,4810.0% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $22.1M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...